Faster access to new drugs doesn't always mean better treatment
- Written by Narcyz Ghinea, Doctoral Researcher, Centre for Values, Ethics and the Law in Medicine, University of Sydney

US President Donald Trump recently chose an adviser to a large pharmaceutical company to lead the country’s drug regulation agency.
Scott Gottlieb – who reportedly sits on the boards of several small drug companies and is an adviser to...